Please login to the form below

Not currently logged in

NICE recommendation

This page shows the latest NICE recommendation news and features for those working in and with pharma, biotech and healthcare.

NICE’s fast-track catapults Skyrizi into market

NICE’s fast-track catapults Skyrizi into market

Watchdog also gives direction on comparing rival treatments. NICE has published a final recommendation for AbbVie and Boehringer Ingelheim’s Skyrizi today, completing a fast-track process which will see the ... The NICE approval means Skyrizi is

Latest news

More from news
Approximately 2 fully matching, plus 127 partially matching documents found.

Latest Intelligence

  • The UK’s new medicines pricing deal – opportunities and risks for pharma The UK’s new medicines pricing deal – opportunities and risks for pharma

    Sciences Council, the NICE Implementation Collaborative (NICE) and the Accelerated Access Collaborative (AAC). ... they see faster uptake in the NHS, they could also leverage that NICE recommendation in other countries too.

  • Positive disruption in business intelligence Positive disruption in business intelligence

    Take the recent recommendation by NICE, the UK’s drug-spending policymaker, of Kadcyla, the breast cancer treatment launched by Roche. ... In December 2016, NICE issued draft guidance indicating Kadcyla was too expensive for routine funding on the NHS.

  • Rare diseases: meeting the challenge Rare diseases: meeting the challenge

    Companies will still need to work hard to win a NICE ‘yes’ recommendation, and may still yet have to accept optimised - as NICE calls them - or restricted - as industry calls them - ... None of the four therapies approved to date under the NICE HST

  • The death of the cancer drugs fund? The death of the cancer drugs fund?

    evidence to support a recommendation for routine commissioning, and where additional evidence would be likely to enable a more informed NICE appraisal decision. ... positive recommendation at which point it would move out of the Fund into mainstream

  • Transforming times at AstraZeneca Transforming times at AstraZeneca

    She gives the example of a drug to prevent a second heart attack that has a positive NICE recommendation, can save people's lives and reduce further hospital costs. ... It sounds like good value and NICE has also said it is,” says Anson.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....